SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/1F16FAA7FAAD5F1FD185DBE71A83A5C21B025FB87202708AF9F760A750EC754F1776DC2507D35E91E1B91FE9E8816FF5>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/1F16FAA7FAAD5F1FD185DBE71A83A5C21B025FB87202708AF9F760A750EC754F1776DC2507D35E91E1B91FE9E8816FF5
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/1F16FAA7FAAD5F1FD185DBE71A83A5C21B025FB87202708AF9F760A750EC754F1776DC2507D35E91E1B91FE9E8816FF5
http://www.w3.org/2000/01/rdf-schema#comment
"The PD-1/CD8 ratio may therefore be a useful prognostic marker for stage II/III CRC. What is important for predicting the prognosis may be the PD-1/CD8 ratio rather than the absolute number of PD-1(+) tumor-infiltrating lymphocytes ."
xsd:string
http://purl.uniprot.org/uniprot/#_F70B9C80F9CA9A7EFD42F1B610C87A2C5F4418411294BEB04D05B67C14D3F62AB67718E0C7ED825A1A4DD0CC70E4709A
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/1F16FAA7FAAD5F1FD185DBE71A83A5C21B025FB87202708AF9F760A750EC754F1776DC2507D35E91E1B91FE9E8816FF5
http://purl.uniprot.org/uniprot/Q8TAW8
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/1F16FAA7FAAD5F1FD185DBE71A83A5C21B025FB87202708AF9F760A750EC754F1776DC2507D35E91E1B91FE9E8816FF5
http://purl.uniprot.org/uniprot/#_Q8TAW8-mappedCitation-28739701
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/1F16FAA7FAAD5F1FD185DBE71A83A5C21B025FB87202708AF9F760A750EC754F1776DC2507D35E91E1B91FE9E8816FF5